Lucence Showcases Liquid Biopsy Tech for Earlier Cancer Detection at 2023 ASCO Annual Meeting

News | May 26, 2023

CHICAGO, IL May 26th, 2023 — Lucence will present promising new data on earlier cancer detection based on AmpliMark, its amplicon-based next generation sequencing technology at the 59th Annual ASCO Meeting in Chicago, June 2-6, 2023.

“Most cancers go undetected until they are at late-stage [1],” said Min-Han Tan, PhD, MBBS, CEO & Medical Director of Lucence. “We look forward to sharing collaborative study results on how earlier cancer detection can be enabled through our liquid biopsy testing.”

Lucence will be presenting the following poster at the ASCO meeting:

#3052 Pek et al. Development and evaluation of a multi-cancer screening (MCS) test for cancers common in Asia. Poster Session: Saturday, June 3rd, from 8.00-11.00AM CDT.

Lucence will share data on a ctDNA mutation-based multi-cancer screening (MCS) liquid biopsy test using its proprietary amplicon-based next-generation sequencing (NGS) testing for detection of cancer-associated alterations. In a cohort of 613 individuals, sensitivity for detection of cancer-associated alterations was 72.7% and specificity was 98.6%. Tissue of origin (TOO) prediction accuracy in an independent 1478-patient cohort was enhanced in 7 of 10 cancers (2 – 50%) by a personalized algorithm including clinico-demographic data. The data demonstrates how amplicon-based NGS supported by a personalized algorithm can support development of a multi-cancer screening test.

Additional key abstracts are available online:

Lucence will be attending the ASCO Annual Meeting in Chicago, Illinois.  To book a meeting with the Lucence team at ASCO, please visit


  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.